Levels of gamma-glutamyl transferase and NT-proBNP in patients with ischemic heart disease and metabolic dysfunction-associated fatty liver disease

Coronary artery disease (CAD) and metabolic-associated fatty liver disease (MAFLD) through similar pathogenetic mechanisms lead to a high risk of cardiovascular complications and mortality. Objective: To study the level of gamma-glutamyl transferase (GGT) and N-terminal pro b-type natriuretic peptide (NT-proBNP) in patients with CAD and MAFLD. Materials and methods: the study included 96 patients with CAD aged 37-78 years. They were divided into 2 groups: 1 - with CAD and MAFLD (n=48); 2 - with CAD without MAFLD (n=48). General clinical parameters; GGT and NT-proBNP levels; FLI, FIB-4 indices; echocardiography were analyzed. Results: Patients with CAD and MAFLD were more likely to be obese, have type 2 diabetes, FLI ≥60 (p=0,002), FIB-4 ≥3,25 (p=0,01) compared to patients without MAFLD. GGT level was higher in patients of group 1 (p=0,045). In the CAD and MAFLD group, stage 2 CHF (p<0,001) and NYHA classes III-IV (p=0,002) were more common. In group 1, NT-proBNP was higher (p=0,003), and ejection fraction was lower (p<0,001). Patients with MAFLD were more likely to have CHFrEF and CHFrEF (p=0,001) compared to patients without MAFLD. Direct correlations between the level of NT-proBNP and GGT; NT-proBNP and FLI and FIB-4 in patients of group 1 were found. In patients with CAD and MAFLD, a significant increase in the level of GGT and NT-proBNP was detected, which is associated with hepatic steatosis, varying degrees of liver fibrosis and more severe course of CHF, the CHFrEF subtype. Thus, patients with CAD and MAFLD have complex interactions between the heart and liver.

coronary heart disease, metabolic-associated fatty liver disease, FLI, FIB-4, gamma-glutamyl transferase, NT-ProBNP

1. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8.

2. Riazi K., Azhari H., Charette J. H. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology. 2022;9:851-861. doi: 10.1016/S2468-1253(22)00165-0.

3. Drapkina O. M., Evstifeeva S. E., Shalnova S. A., et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies). Cardiovascular Therapy and Prevention. 2025;24(2):4316. (In Russ.)doi: 10.15829/1728-8800-2025-4316.@@ Драпкина О. М., Евстифеева С. Е., Шальнова С. А. и соавт. Распространненость неалькогольной жировой болезни печени и ее ассоциации с сердечно-сосудистыми факторами риска (данные российский эпидемиологических исследований). Кардиоваскулярная терапия и профилактика. 2025; 24(2):4316. doi: 10.15829/1728-8800-2025-4316.

4. Kasper P., Martin A., Lang S. et al. NAFLD and cardiovascular diseases: a clinical review. Clinical Research in Cardiology. 2021;110(7):921-937. doi: 10.1007/s00392-020-01709-7.

5. Lazarus J. V., Mark H. E., Anstee Q. M. et al. NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology. 2022;19(1):60-78.doi: 10.1038/s41575-021-00523-4.

6. Eslam M., Newsome P. N., Sarin S. K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology. 2020;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039.

7. Zhang Z., Zheng M., Lei H. et al. A clinical study of the correlation between metabolic-associated fatty liver disease and coronary plaque pattern. Scientific Reports. 2023;13(7224). doi: 10.1038/s41598-023-34462-8.

8. Lee D. H., Blomhoff R., Jacobs D. R. Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radical Research. 2004;38(6):535-9. doi: 10.1080/10715760410001694026.

9. Ali S. S., Oni E. T., Blaha M. J. et al. Elevated gamma-glutamyl transferase is associated with subclinical inflammation independent of cardiometabolic risk factors in an asymptomatic population: a cross-sectional study. Nutrition & Metabolism. 2016;13:37. doi: 10.1186/s12986-016-0097-7.

10. Paolicchi A., Emdin M., Ghliozeni E. et al. Images in cardiovascular medicine. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation. 2004;109(11):1440. doi: 10.1161/01.

11. Mantovani A., Petracca G., Csermely A. et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2022;72:372-380. doi: 10.1136/gutjnl-2022-327672.

12. Qiu M., Li J., Hao S. et al. Non-alcoholic fatty liver disease is associated with a worse prognosis in patients with heart failure: A pool analysis. Frontiers in Endocrinology. 2023;14:1167608. doi: 10.3389/fendo.2023.1167608.

13. Zethelius B., Berglund L., Sundström J. et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. The New England Journal of Medicine. 2008;358(20):2107-16. doi: 10.1056/NEJMoa0707064.

14. Chaulin A. M., Duplyakov D. V. Increased natriuretic peptides not associated with heart failure.Russian Journal of Cardiology. 2020;25(4S):4140. (In Russ.) doi: 10.15829/1560-4071-2020-4140.@@ Чаулин А. М., Дупляков Д. В. Повышение натрийуретических пептидов, не ассоциированное с сердечной недостаточностью. Российский кардиологической журнал. 2020;25(4S):4140. doi: 10.15829/1560-4071-2020-4140.

15. Qiao Z. P., Zheng K. I., Zhu P. W. et al. Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. Nutrition, Metabolism and Cardiovascular Diseases. 2020;30(10):1820-1825. doi: 10.1016/j.numecd.2020.05.017.

16. Kim J. H., Moon J. S., Byun S. J. et al. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. Cardiovascular Diabetology. 2020;19(1):51. doi: 10.1186/s12933-020-01025-4.

17. Baratta F., Pastori D., Angelico F. et al. Nonalcoholic Fatty Liver Disease and Fibrosis Associated with Increased Risk of Cardiovascular Events in a Prospective Study. Clinical Gastroenterology and Hepatology. 2020;18(10):2324-2331. doi: 10.1016/j.cgh.2019.12.026.

18. Higashiura Y., Tanaka M., Mori K. et al. High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population. European Heart Journal Open. 2022;2(3): oeac030. doi: 10.1093/ehjopen/oeac030.

19. Park J., Kim G., Kim H. et al. The association of hepatic steatosis and fibrosis with heart failure and mortality. Cardiovascular Diabetology. 2021;20(1):197. doi: 10.1186/s12933-021-01374-8.

20. Nguyen K., Fan W., Bertoni A. et al. N-terminal Pro B-type Natriuretic Peptide and High-sensitivity Cardiac Troponin as Markers for Heart Failure and Cardiovascular Disease Risks According to Glucose Status (from the Multi-Ethnic Study of Atherosclerosis [MESA]). American Journal of Cardiology. 2020;125(8):1194-1201. doi: 10.1016/j.amjcard.2020.01.025.

21. Stolbova S. K., Dragomiretskaya N. A., Beliaev I. G., Podzolkov V. I. Clinical and laboratory associations of liver fibrosis indexes in patients with decompensated Chronic Heart Failure II-IV Functional Classes. Kardiologiia. 2020;60(5):90-99. (In Russ.) doi: 10.18087/cardio.2020.5.n920.@@ Столбова С. К., Драгомирецкая Н. А., Беляев Ю. Г., Подзолков В. И. Клинико-лабораторные ассоциации индексов печеночного фиброза у больных с декомпенсацией хронической сердечной недостаточности II-IV функциональных классов. Кардиология. 2020;60(5):90-99. doi: 10.18087/cardio.2020.5.n920.

22. Cicero A. F.G, Gitto S., Fogacci F. et al. Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study. European Journal of Internal Medicine. 2018;53:29-33. doi: 10.1016/j.ejim.2018.03.010.

23. Harrison S. A., Oliver D., Arnold H. L. et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441-1447. doi: 10.1136/gut.2007.146019.

24. Nadkarni A., Garber A., Costa S. et al. Auditing the AUDIT: A systematic review of cut-off scores for the Alcohol Use Disorders Identification Test (AUDIT) in low- and middle-income countries. Drug and Alcohol Dependence. 2019;202:123-133. doi: 10.1016/j.drugalcdep.2019.04.031.

25. Wong V. W., Wong G. L., Tsang S. W. et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Alimentary Pharmacology & Therapeutics. 2009;29:387-396. doi: 10.1111/j.1365-2036.2008.03896.

26. Bobylev Y. M., Vladimirsky V. E., Katkova A. A. Non-alcoholic fatty liver disease in patients with hypertension. Ural Medical Journal. 2019;(2):58-63. (In Russ.) doi: 10.25694/URMJ.2019.02.28.@@ Бобылев Ю. М., Владимирский В. Е., Каткова А. А. Неалкогольная жировая болезнь печени у пациентов с гипертонической болезнью. Уральский медицинский журнал. 2019;(2):58-63. doi: 10.25694/URMJ.2019.02.28.

27. Cho E. J., Han K., Lee S. P. et al. Liver enzyme variability and risk of heart disease and mortality: A nationwide population-based study. Liver International. 2020;40(6):1292-1302. doi: 10.1111/liv.14432.

28. Li N., Dong X., Zhu C. et al. Association study of NAFLD with pericoronary adipose tissue and pericardial adipose tissue: Diagnosis of stable CAD patients with NAFLD based on radiomic features. Nutrition, Metabolism and Cardiovascular Diseases. 2025;35(1):103678. doi: 10.1016/j.numecd.2024.06.020.

29. Ho F. K., Ferguson L. D., Celis-Morales C. A. et al. Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. eClinicalMedicine. 2022;48:101435. doi: 10.1016/j.eclinm.2022.101435.

30. Xuan C., Li J., Liu R. H. et al. Association between serum gamma-glutamyltransferase and early-onset coronary artery disease: a retrospective case-control study. Annals of Medicine. 2023;55(2):2289606. doi: 10.1080/07853890.2023.2289606.

31. He L., Chen S., Zhu X., He F. Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio: A valuable predictor of coronary heart disease incidence. Nutrition, Metabolism and Cardiovascular Diseases. 2025;35(5):103775. doi: 10.1016/j.numecd.2024.10.013.

32. Carli F., Sabatini S., Gaggini M. et al. Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk.International Journal of Molecular Sciences. 2023;24(19):14651. doi: 10.3390/ijms241914651.

33. McNally B. B., Rangan P., Wijarnpreecha K., Fallon M. B. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease. Digestive Diseases and Sciences. 2023;68(9):3765-3773. doi: 10.1007/s10620-023-07987-1.

34. Boeckmans J., Prochaska J. H., Gieswinkel A. et al. Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study. The Lancet Regional Health - Europe. 2024;48:101153. doi: 10.1016/j.lanepe.2024.101153.

35. Buzas R., Ciubotaru P., Faur A. C. et al. Correlation of the FIB-4 Liver Biomarker Score with the Severity of Heart Failure. Medicina (Kaunas). 2024;60(12):1943. doi: 10.3390/medicina60121943.

36. Mishra R. K., Beatty A. L., Jaganath R. et al. B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Journal of the American Heart Association. 2014;3(4): e000907. doi: 10.1161/JAHA.114.000907.

37. VanWagner L. B., Wilcox J. E., Ning H. et al. Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA study. Journal of the American Heart Association. 2020;9(4): e014279. doi: 10.1161/JAHA.119.014279.

38. Paulus W. J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013;62(4):263-71. doi: 10.1016/j.jacc.2013.02.092.

39. El Hadi H., Di Vincenzo A., Vettor R., Rossato M. Relationship between Heart Disease and Liver Disease: A Two-Way Street. Cells. 2020;9(3):567. doi: 10.3390/cells9030567.